Get started
Author

Abhijit Vaidya

Observed names: Abhijit J. Vaidya, AbhijitJ Vaidya, Vaidya Abhijit
Institution: Cipla (India)
ORCID: 0000-0002-6046-9105
Observed ORCID: 0000-0002-6046-9105
OpenAlex ID: A5057002220
Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India
2015 · Sau L. Lee, Bhawana Saluja, et al. · The AAPS Journal · 71
Device-handling study of a novel breath-actuated inhaler, Synchrobreathe®, versus a pMDI
2019 · Santhalingam Balamurugan, Komalkirti Apte, et al. · Respiratory Medicine · 15
Priming of beta-2 agonist and antimuscarinic induced physiological responses induced by 1200 mg/day NAC in moderate to severe COPD patients: A pilot study
2013 · Ravikumar Sinojia, Moin Shaikh, et al. · Respiratory Physiology & Neurobiology · 11
Comparison of fluticasone/formoterol with budesonide/formoterol pMDI in adults with moderate to severe persistent asthma: Results from a 12-week randomized controlled trial
2017 · Akash Balki, S. Balamurugan, et al. · Pulmonary Pharmacology & Therapeutics · 9
Real-world evaluation of the clinical safety and efficacy of fluticasone/formoterol FDC via the Revolizer® in patients with persistent asthma in India
2019 · Aloke Ghoshal, Pradyut Waghray, et al. · Pulmonary Pharmacology & Therapeutics · 7
Newer therapies for chronic obstructive pulmona disease.
2012 · Rahul Kodgule, Abhijit Vaidya, et al. · PubMed · 5
Evaluation of effectiveness and tolerability of a moisturiser as an adjuvant to isotretinoin therapy for acne: a real-world evidence
2023 · Sushil T. Tahiliani, Vinay V. Saraf, et al. · International Journal of Research in Dermatology · 4
PDF
Effectiveness and safety of salmeterol/fluticasone fixed-dose combination delivered through Synchrobreathe ® in patients with asthma: the real-world EVOLVE study
2022 · Santhalingam Balamurugan, Dalal Sonia, et al. · Therapeutic Advances in Respiratory Disease · 4
A randomized, double-blind study comparing the efficacy and safety of a combination of formoterol and ciclesonide with ciclesonide alone in asthma subjects with moderate-to-severe airflow limitation
2016 · SundeepS Salvi, AbhijitJ Vaidya, et al. · Lung India · 4
Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study
2022 · Sundeep Salvi, Anand Kumar, et al. · Lung India · 3
Safety and efficacy of inhaled itraconazole in adults with asthma and allergic bronchopulmonary aspergillosis (PUR1900-ABPA): a randomized, double-blind, parallel group, placebo-controlled, multicenter, phase 2 trial
2026 · Ritesh Agarwal, Dhruv Chaudhary, et al. · European Respiratory Journal · 2
Comparison of a portable, pneumotach flow-sensor–based spirometer (Spirofy™) with the vitalograph alpha Touch™ spirometer in evaluating lung function in healthy individuals, asthmatics, and COPD patients—a randomized, crossover study
2024 · Deepak Talwar, S Balamurugan, et al. · BMC Pulmonary Medicine · 2
Efficacy and Tolerability of a New HFA-Propelled Fluticasone/Formoterol Combination Inhaler Compared to Budesonide/Formoterol Combination in Subjects With Moderate to Persistent Asthma
2010 · Jaideep A. Gogtay, Akash Balki, et al. · CHEST Journal · 2
Outcomes and Usability of Formoterol-Budesonide Delivered Through Synchrobreathe® in Patients With Chronic Obstructive Pulmonary Disease: The EMERGE Study
2025 · Santhalingam Balamurugan, Himanshu Pophale, et al. · Drugs - Real World Outcomes · 1
PDF
Real-world study of formoterol/budesonide delivered through BAI in COPD patients
2023 · Santhalingam Balamurugan, Himanshu Pophale, et al. · European Respiratory Journal · 1
Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD
2019 · Sundeep Salvi, Anand Kumar, et al. · European Respiratory Journal · 1
LATE-BREAKING ABSTRACT: Effects of a fixed dose once-daily triple drug combination in smokers and non-smokers with COPD
2016 · Ashish Kumar Deb, Mayank Agarwal, et al. · European Respiratory Journal · 1
Clinical evaluation of fluticasone/formoterol twice daily delivered via a single dose dry powder inhaler in patients with persistent asthma
2016 · Pradyut Waghray, Mahip Saluja, et al. · European Respiratory Journal · 1
General physicians’ experience and perception of symptoms control in patients of asthma changed to branded generic formulation of Salmeterol/Fluticasone in Spain: The ORIGEN study
2025 · Jorge Rábago Castro, Belen López-Muñiz Ballesteros, et al. · European Respiratory Journal
Late Breaking Abstract - A phase 2, dose-finding study of inhaled itraconazole in ABPA-complicating asthma
2025 · Ritesh Agarwal, Dhruva Chaudhry, et al. · European Respiratory Journal
Efficacy of Budesonide/Glycopyrronium/Formoterol FDC across blood eosinophil ranges in Indian COPD patients: post-hoc analysis of a phase-IV clinical-trial
2024 · Priti Meshram, Manish Jain, et al. · European Respiratory Journal
Author response for "Effectiveness and safety of salmeterol/fluticasone fixed-dose combination delivered through Synchrobreathe® in patients with asthma: the real-world EVOLVE study"
2022 · Santhalingam Balamurugan, Dalal Sonia, et al. · Publons reviews and discussion
Fixed-dose combination of three drugs, i.e. LABA/LAMA/ICS for COPD: Results of a real-world study from India
2020 · Sundeep Salvi, Ashish Kumar Deb, et al. · Pulmonary Pharmacology & Therapeutics
Device handling study of a novel breath-actuated inhaler Synchrobreathe vs pMDI
2019 · Santhalingam Balamurugan, Komalkirti Apte, et al. · European Respiratory Journal
Author's reply
2017 · Sundeep Santosh Salvi, Abhijit Vaidya, et al. · Lung India
Works count: 26
Citation count: 144
H-index: 5
I10-index: 3
Year
Topic
Type